<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00879073</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-15690</org_study_id>
    <nct_id>NCT00879073</nct_id>
  </id_info>
  <brief_title>Study Bendamustine Concurrent Whole Brain Radiation Brain Metastases From Solid Tumors</brief_title>
  <official_title>Phase I Study of Bendamustine With Concurrent Whole Brain Radiation Therapy in Patients With Brain Metastases From Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Comprehensive Cancer Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cephalon</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to:&#xD;
&#xD;
        -  Test the maximum tolerated dose (MTD) of Bendamustine with whole brain radiation therapy&#xD;
           (WBRT)&#xD;
&#xD;
        -  To determine the plasma pharmacokinetics (a blood test to see how much of the drug is&#xD;
           getting into the patient's system and how long it lasts in the system) of Bendamustine&#xD;
&#xD;
        -  To determine the presence of Bendamustine in cerebrospinal fluid (CSF) (fluid from the&#xD;
           brain and spinal cord) of study patients Bendamustine is approved by the Food and Drug&#xD;
           Administration (FDA) for chronic lymphocytic leukemia. However, Bendamustine will be&#xD;
           used in this study as an investigational agent.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bendamustine will be started in the first group at a dose of 60 mg/m²; patients in group 2&#xD;
      will be given Bendamustine at a dose of 80 mg/m²; patients in Group 3 will be given&#xD;
      Bendamustine at 100 mg/m². Each cohort will receive Bendamustine once weekly for a total of 4&#xD;
      weeks.&#xD;
&#xD;
      Approximately 3-6 patients enrolled in this study will receive lumbar punctures. Patients&#xD;
      will be told before study enrollment whether they will have a lumbar puncture to withdraw&#xD;
      CSF.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Principal Investigator is leaving Moffitt&#xD;
  </why_stopped>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>24 Weeks per Patient</time_frame>
    <description>To determine the MTD of bendamustine in combination with WBRT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs)</measure>
    <time_frame>24 Weeks per Patient</time_frame>
    <description>To determine the toxicity profile of bendamustine in combination with WBRT</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>A - Cohort 1 Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1: Bendamustine 60 mg/m² x 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B - Cohort 2 Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2: Bendamustine 80 mg/m² x 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C - Cohort 3 Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 3: Bendamustine 100 mg/m² x 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>Approximately 15-24 study patients will be enrolled in this Phase I trial. Study patients will receive a weekly dose of IV bendamustine with whole brain radiation therapy for 3 weeks and then receive a fourth dose of IV bendamustine one week after completion of whole brain radiation therapy. The first dose of IV bendamustine will be given when whole brain radiation is initiated.</description>
    <arm_group_label>A - Cohort 1 Treatment</arm_group_label>
    <arm_group_label>B - Cohort 2 Treatment</arm_group_label>
    <arm_group_label>C - Cohort 3 Treatment</arm_group_label>
    <other_name>Treanda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathologically (histologically or cytologically) proven diagnosis of solid tumor&#xD;
             malignancy within 5 years of registration. Pathological confirmation by pathologists&#xD;
             at Moffitt Cancer Center is required.&#xD;
&#xD;
          -  Cerebral metastases from known solid tumors diagnosed by contrast-enhanced brain&#xD;
             magnetic resonance imaging (MRI) or contrast-enhanced head computed tomography (CT)&#xD;
             for patients unable to receive MRIs&#xD;
&#xD;
          -  Single metastases that have been resected&#xD;
&#xD;
          -  Patient may have had prior radiosurgery or surgical resection for brain metastasis.&#xD;
             Patients should have completed prior therapy at least 14 days but no longer than 56&#xD;
             days prior to study entry.&#xD;
&#xD;
          -  Karnofsky Performance Status ≥ 70 within 28 days prior to study entry.&#xD;
&#xD;
          -  Expected life span of ≥ 3 months&#xD;
&#xD;
          -  Able to tolerate 3 week course of whole brain radiation therapy&#xD;
&#xD;
          -  Able to receive a lumbar puncture (for post-MTD patients only)&#xD;
&#xD;
          -  Adequate bone marrow, liver and renal function as assessed by the following:&#xD;
             Hemoglobin &gt; 9.0 g/dl; Absolute neutrophil count (ANC) &gt; 1,500/mm³; Platelet count &gt;&#xD;
             100,000/mm³; Total bilirubin &lt; 1.5 x upper limit of normal (ULN); Alanine&#xD;
             transaminase/Aspartic transaminase (ALT/AST) &lt; 2.5 x the ULN (&lt; 5 x ULN for patients&#xD;
             with liver involvement); International normalized ratio (INR) &lt; 1.5 or a prothrombin&#xD;
             time/partial thromboplastin time (PT/PTT) within normal limits; Creatinine &lt; 1.5 x ULN&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum pregnancy test performed&#xD;
             within 7 days prior to the start of treatment.&#xD;
&#xD;
          -  Ability to understand and sign a study-specific written informed consent prior to&#xD;
             study entry.&#xD;
&#xD;
          -  Patients receiving systemic therapy are eligible for this study if given &gt;14 days&#xD;
             prior to study entry and given no sooner than &gt;14 days post radiation therapy (RT)&#xD;
             completion.&#xD;
&#xD;
          -  Complete history and general physical examination within 28 days prior to study entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to bendamustine or mannitol&#xD;
&#xD;
          -  Patients with cerebral metastases from unknown primary tumors&#xD;
&#xD;
          -  Patients with cerebral metastases from leukemias or lymphomas&#xD;
&#xD;
          -  Patients with uncontrolled systemic cancer (i.e. evidence of systemic disease&#xD;
             progression &lt; 3 months prior to study entry)&#xD;
&#xD;
          -  Systemic chemotherapy ≤14 days prior to study entry or ≤14 days after completing&#xD;
             radiotherapy&#xD;
&#xD;
          -  Patients who received prior BCNU wafer (Gliadel®) implantation for surgically resected&#xD;
             cerebral metastatic lesions&#xD;
&#xD;
          -  Patients with a life expectancy of less than 3 months&#xD;
&#xD;
          -  Patients who received prior whole brain radiation therapy. As noted above, patients&#xD;
             who received prior radiosurgery are allowed&#xD;
&#xD;
          -  Patients with significant hydrocephalous&#xD;
&#xD;
          -  Active clinically serious infection &gt; Common Terminology Criteria for Adverse Events&#xD;
             (CTCAE) Grade 2&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Pan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.moffitt.org/research--clinical-trials/clinical-trials</url>
    <description>Moffitt Cancer Center Clinical Trials website</description>
  </link>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>April 8, 2009</study_first_submitted>
  <study_first_submitted_qc>April 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2009</study_first_posted>
  <last_update_submitted>December 17, 2012</last_update_submitted>
  <last_update_submitted_qc>December 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brain and Nervous System</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

